Loading…
Monte Rosa Therapeutics, Inc. is projected to rise to $25.69 by 2027, a +34% move from its current price of $19.17. GLUE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $18.70 | $19.17 | $19.65 | 0.00% |
| May 30 | $18.51 | $19.17 | $19.85 | 0.00% |
| May 31 | $18.37 | $19.17 | $20.01 | 0.00% |
| Jun 1 | $18.24 | $19.17 | $20.14 | 0.00% |
| Jun 2 | $18.14 | $19.17 | $20.26 | 0.00% |
| Jun 3 | $18.04 | $19.17 | $20.37 | 0.00% |
| Jun 4 | $17.96 | $19.17 | $20.47 | 0.00% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $17.96 | $19.17 | $20.47 | 0.00% |
| Week 2 | $17.47 | $19.17 | $21.03 | 0.00% |
| Week 3 | $17.11 | $19.17 | $21.47 | 0.00% |
| Week 4 | $16.82 | $19.17 | $21.85 | 0.00% |
| Week 5 | $16.56 | $19.17 | $22.19 | 0.00% |
| Week 6 | $16.33 | $19.17 | $22.50 | 0.00% |
| Week 7 | $16.12 | $19.17 | $22.79 | 0.00% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company that develops novel small molecule precision medicines. These medicines are designed to employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.
GLUE trades as a healthcare stock with a current price of $18.81 and a market capitalization of $1.59B. It is ranked 2184 by market capitalization.
A major floor 23.2% below — a decisive break under it would weaken the trend.
The nearest floor, 8.3% below — buyers have tended to step in here.
The nearest ceiling, 9.4% above — a clean break opens room to run.
A major ceiling 27.5% above — clearing it would confirm fresh momentum.
Key GLUE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GLUE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $18.94 | Buy | $18.94 | Buy |
| MA 10 | $18.61 | Buy | $18.87 | Buy |
| MA 20 | $19.03 | Buy | $18.88 | Buy |
| MA 50 | $18.11 | Buy | $18.59 | Buy |
| MA 100 | $19.00 | Buy | $17.76 | Buy |
| MA 200 | $14.78 | Buy | $15.36 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.08 | Neutral |
| Stoch RSI (14) | 65.96 | Neutral |
| CCI (20) | 18.11 | Neutral |
| Williams %R (14) | -40.67 | Info |
| MACD (12,26,9) | -0.05 | Sell |
| ROC (12) | -1.13 | Sell |
| Bollinger %B (20,2) | 0.55 | Neutral |
| Stochastic %K (14) | 59.33 | Neutral |
| TRIX (15) | 0.10 | Buy |
| Awesome (5,34) | -0.11 | Sell |
| Ultimate (7,14,28) | 59.84 | Neutral |
| Momentum (10) | 0.06 | Buy |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 19.28 | Sell |
| ADX (14) | 11.50 | Neutral |
| ATR (14) | 0.44 | Info |
The 30-day technical picture shows a bullish tilt with RSI(14) at 50, suggesting neutral momentum around the midline. The stock is trading above the SMA50 of $17.99 and above the SMA200 of $14.63, indicating a positive near-term trend.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $14.40 | $19.17 | $27.24 | 0% | Neutral | |
| $20.56 | $25.69 | $33.89 | +34% | Bullish | |
| $21.51 | $27.53 | $37.54 | +44% | Bullish | |
| $24.45 | $31.95 | $44.70 | +67% | Bullish | |
| $24.53 | $32.64 | $46.68 | +70% | Bullish | |
| $24.44 | $33.05 | $48.20 | +72% | Bullish | |
| $27.92 | $38.33 | $56.88 | +100% | Bullish | |
| $31.20 | $43.46 | $65.52 | +127% | Bullish | |
| $36.24 | $51.17 | $78.28 | +167% | Bullish | |
| $38.92 | $55.67 | $86.33 | +190% | Bullish | |
| $51.88 | $78.70 | $129.22 | +311% | Bullish | |
| $88.12 | $147.76 | $263.81 | +671% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $14.40 | $19.17 | $22.52 | +0.00% |
| June 2026 | $16.27 | $19.07 | $22.85 | -0.53% |
| July 2026 | $16.23 | $19.17 | $23.25 | +0.52% |
| August 2026 | $16.91 | $20.09 | $24.60 | +4.82% |
| September 2026 | $17.27 | $20.61 | $25.44 | +2.60% |
| October 2026 | $17.12 | $20.54 | $25.52 | -0.38% |
| November 2026 | $17.42 | $20.98 | $26.23 | +2.16% |
| December 2026 | $17.92 | $21.66 | $27.24 | +3.25% |
Click any year to see its month-by-month GLUE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, GLUE could reach as high as $27.24, with a base case around $19.17 and support toward $14.40 — roughly 0% from $19.17. Price action looks broadly range-bound.
Expect GLUE to range from $20.56 to $33.89 through 2027. The $25.69 average target implies a +34% move from current prices. That is up +34% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The GLUE price prediction for 2028 points to an average of $27.53 (low $21.51, high $37.54) — a potential gain of +44% on today's $19.17. Momentum favours further upside here.
In 2029, GLUE is projected to trade between $24.45 and $44.70, averaging $31.95 — a potential gain of +67% from today's $19.17. That is up +16% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Monte Rosa Therapeutics, Inc.'s 2030 outlook centres on $32.64, within a $24.53 to $46.68 range. That is up +2% on the projected 2029 average. That marks a +70% change versus current levels. Momentum favours further upside here.
By 2031, GLUE could reach as high as $48.20, with a base case around $33.05 and support toward $24.44 — roughly +72% from $19.17. Buyers look set to stay in control over this stretch.
Expect GLUE to range from $27.92 to $56.88 through 2032. The $38.33 average target implies a +100% move from current prices. That is up +16% on the projected 2031 average. Momentum favours further upside here.
The GLUE price prediction for 2033 points to an average of $43.46 (low $31.20, high $65.52) — a potential gain of +127% on today's $19.17. Buyers look set to stay in control over this stretch.
In 2034, GLUE is projected to trade between $36.24 and $78.28, averaging $51.17 — a potential gain of +167% from today's $19.17. That is up +18% on the projected 2033 average. Momentum favours further upside here.
Monte Rosa Therapeutics, Inc.'s 2035 outlook centres on $55.67, within a $38.92 to $86.33 range. That is up +9% on the projected 2034 average. That marks a +190% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, GLUE could reach as high as $129.22, with a base case around $78.70 and support toward $51.88 — roughly +311% from $19.17. Momentum favours further upside here.
Expect GLUE to range from $88.12 to $263.81 through 2050. The $147.76 average target implies a +671% move from current prices. That is up +88% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in GLUE today (≈ 52.164841 GLUE) could be worth
$7,707.7
+$6,707.7 (+671%) by 2050 · US Dollar
Based on the average projected GLUE price of $147.76 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GLUEwould be worth at today's price.
$1,000 invested in GLUE on May 27, 2025 (≈ 250.626566 GLUE) would be worth
$4,804.51
+$3,804.51 (+380.5%) today · 4.80× · US Dollar
Based on a GLUE entry price of $3.99 vs. today's $19.17.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $18.65 | $1,027.88 | +2.8% |
| 1 month ago | $19.29 | $993.78 | -0.6% |
| 3 months ago | $18.5 | $1,036.22 | +3.6% |
| 6 months ago | $16.17 | $1,185.53 | +18.6% |
| 1 year ago | $3.99 | $4,804.51 | +380.5% |
| All time (4.9y) ago | $21.18 | $905.1 | -9.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GLUE forecast.
Our base-case forecast reaches $38.00 around 2032.
Implied market cap at $38.00: $3.21B
The multi-year forecast points to a continued bullish trajectory, with the 2027 average price at $24.91 and a 2027 max of $33.08 (ROI 32.4%). The 2030 forecast shows an average price of $30.97 with a max of $44.74 (ROI 64.7%), and the sentiment remains bullish across these years. By 2040, the average is $72.59 with a max of $120.98 (ROI 285.9%), and by 2050 the average reaches $133.72 with a max of $243.02 (ROI 610.9%), reflecting a strong growth outlook but with the customary uncertainty of future market conditions.
The forecast consistently labels sentiment as BULLISH beyond 2026, and the annualized volatility is shown at 50%.
Tap a question to reveal the answer.
The 2026 forecast shows an average price of $18.81, with a range from $14.40 to $26.75 (sentiment NEUTRAL).
Forecasts show rising averages and positive ROI after 2026, with ROI reaching 32.4% in 2027 and up to 610.9% by 2050, though near-term ROI is 0% in 2026 and volatility is high (annualized 50%).
Yes. The forecast max reaches $120.98 in 2040 and $243.02 in 2050, while the 2040 average is $72.59 and the 2050 average is $133.72.
Current price is $18.81 and market cap is $1.59B.
The 2027 forecast shows min $19.84, average $24.91, max $33.08, with ROI 32.4% and sentiment BULLISH.
Monte Rosa Therapeutics, Inc. Community Discussion
0Share your Monte Rosa Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.